Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H7NO.C4H6O6 |
Molecular Weight | 259.2127 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CN=CC=C1.O[C@H]([C@@H](O)C(O)=O)C(O)=O
InChI
InChIKey=NPORIZAYKBQYLF-LREBCSMRSA-N
InChI=1S/C6H7NO.C4H6O6/c8-5-6-2-1-3-7-4-6;5-1(3(7)8)2(6)4(9)10/h1-4,8H,5H2;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H7NO |
Molecular Weight | 109.1259 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Other AEs: Increased appetite, Skin rash... Other AEs: Increased appetite (15%) Sources: Skin rash (36%) Itching (37%) Flushing (68%) Nausea (50%) Abdominal pain (15%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Increased appetite | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Skin rash | 36% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Itching | 37% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Nausea | 50% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Flushing | 68% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Reaction of the tobacco alkaloid myosmine with hydrogen peroxide. | 2006 Jan |
|
Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification. | 2006 Nov |
|
Enzymatic oxidation of NADP+ to its 4-oxo derivative is a side-reaction displayed only by the adrenodoxin reductase type of ferredoxin-NADP+ reductases. | 2007 Aug |
|
catena-Poly[[tetrakis(mu-propionato-kappa(2)O:O')dicopper(II)]-mu-3-pyridylmethanol-kappa(2)N:O-[bis(propionato-kappaO)bis(3-pyridylmethanol-kappaN)copper(II)]-mu-3-pyridylmethanol-kappaO:N]. | 2007 Mar |
|
Noncovalent synthesis of hierarchical zinc phosphates from a single Zn(4)O(12)P(4) double-four-ring building block: dimensionality control through the choice of auxiliary ligands. | 2010 Jan 18 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13383231
25 mg tablet 4 times a daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:26:18 GMT 2023
by
admin
on
Fri Dec 15 15:26:18 GMT 2023
|
Record UNII |
5G605ZIE90
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
235354
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | RxNorm | ||
|
147492
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
m7882
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | Merck Index | ||
|
5G605ZIE90
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
SUB14652MIG
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
228-199-1
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
DTXSID90977232
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
C77152
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
100000079995
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
93578
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
6164-87-0
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL1235535
Created by
admin on Fri Dec 15 15:26:18 GMT 2023 , Edited by admin on Fri Dec 15 15:26:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |